Open access
70
Views
0
CrossRef citations to date
0
Altmetric
STUDY PROTOCOL
Randomized, Double-Blind, Placebo-Controlled, Phase I, Dose- Escalation Study to Evaluate the Tolerance, Pharmacokinetics, Pharmacodynamics and Immunogenicity of PEGylated Urate Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers: Study Protocol
Feifei Sun1 Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of China
https://orcid.org/0000-0002-8161-536XView further author information
Chenjing Wang1 Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of ChinaView further author information
, Yi Xu1 Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of ChinaView further author information
, Pingping Lin1 Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of ChinaView further author information
, Yaozhong Cao2 Clinical Medical Center, Xiuzheng Pharmaceutical Group, Hangzhou, Zhejiang, People’s Republic of ChinaView further author information
, Jiahui Zhang3 Xiuzheng Bio-Medicine Research Institute, Hangzhou, Zhejiang, People’s Republic of ChinaView further author information
, Xin Li1 Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of ChinaView further author information
, Xin Jiang1 Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of ChinaView further author information
, Yao Fu1 Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of ChinaView further author information
& Yu Cao1 Clinical Trials Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People’s Republic of ChinaCorrespondence[email protected]
https://orcid.org/0000-0002-3980-8133View further author information
Pages 4263-4268
|
Received 10 Aug 2023, Accepted 19 Dec 2023, Published online: 28 Dec 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.